Cerevel Therapeutics Holdings Inc.

Cerevel Therapeutics Holdings Inc.

World Rank (Jan-05-2024)
2,079
Market Cap (Jan-05-2024)
7.635 Billion USD
World Rank (Jul-30-2023)
3,086
Market Cap (Jul-30-2023)
4.779 Billion USD
World Rank (Jan-07-2022)
3,528
Market Cap (Jan-07-2022)
4.555 Billion USD
Headquarters Country
USA
Nasdaq / NYSE Code
CERE
Employee Count
298
Employee Count as of Date
As on 2022
Headquarters City/State
Massachusetts
World Region
Americas
World Subregion
Northern America
Annual Revenue in USD
0 Million USD
Annual Operating Income in USD
-367 Million USD
Annual Net Income in USD
-351 Million USD
Annual Results for Period Ending
Dec-2022 ending year
Total Assets in USD
1,017 Million USD
Total Liabilities in USD
496 Million USD
Total Equity in USD
521 Million USD
Balance Sheet for Period Ending
Dec-2022 ending year
Business Sector
Healthcare
Biotechnology
Biopharmaceutical
Company Website
CEREVEL THERAPEUTICS HOLDINGS, INC.
Company Profile

Cerevel Therapeutics Holdings is a clinical stage biopharmaceutical company that combines a deep understanding of the biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) receptor pharmacology to discover and develop new therapies. The headquarters is in USA.

Annual Results Summary

CEREVEL THERAPEUTICS HOLDINGS, INC. - Yearly Revenue and Net Income - in Million USD:

Year - EndingRevenueOperating IncomeNet Income
Dec-20220-367 (Loss)-351 (Loss)
Dec-20210-220 (Loss)-225 (Loss)
Dec-20200-149 (Loss)-152 (Loss)
Dec-20190-83 (Loss)-128 (Loss)
Balance Sheet Summary

Total Assets as on Dec-2022 was 1,017 Million USD.

Total Liabilities as on Dec-2022 was 496 Million USD.

Total Equity as on Dec-2022 was 521 Million USD.

Founded Year
2018
IPO Year
2020
Stock Exchange
NYSE
Nasdaq Sector
Health Care
Nasdaq Industry
Biotechnology: Pharmaceutical Preparations

Share